Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Score, Valuation & Financial Research

Rapport Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RAPP

Rapport Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 28.33. These figures are a research snapshot, not a buy or sell recommendation.

What Rapport Therapeutics, Inc. Common Stock does

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Rapport Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research, discovery, and development of small molecule precision medicines for neurological and psychiatric disorders, funded primarily through equity financing and capital raises.

Products and services

  • The company is developing a pipeline of precision neuromedicines, with its lead clinical candidate, RAP-219, currently being advanced into Phase 3 trials for the treatment of drug-resistant focal onset seizures (FOS).

Business relationships and partnerships

  • Johnson & Johnson Innovation-JJDC — Founding support and strategic investment partner involved in the formation and advancement of the company's RAP-targeted precision neuromedicines. Source

Business strengths to evaluate

  • Proprietary RAP platform for brain region specificity Source
  • Positive Phase 2a proof-of-concept clinical trial results for RAP-219 Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of clinical-stage product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RAPP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 28.33
Market capitalization:
1.36B (currency not supplied)
Revenue:
USD 20M
Net income:
USD -137.16M
Free cash flow:
USD -88.09M
Cash:
USD 63.61M
Total debt:
USD 10.11M
EPS:
USD -3.04

What stands out

  • Free cash flow is USD -88.09M, negative for the stored period.
  • The balance sheet shows USD 63.61M of cash versus USD 10.11M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -440.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -685.8% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 53.51M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RAPP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RAPP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RAPP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RAPP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of RAPP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RAPP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.